Academic Journal

CD19 CAR-T cell therapy: a new dawn for autoimmune rheumatic diseases?

التفاصيل البيبلوغرافية
العنوان: CD19 CAR-T cell therapy: a new dawn for autoimmune rheumatic diseases?
المؤلفون: Rangel-Peláez, Carlos, Martínez-Gutiérrez, Laura, Tristán-Manzano, María, Callejas, José Luis, Ortego-Centeno, Norberto, Martín, Francisco, Martín, Javier
المصدر: Frontiers in Immunology ; volume 15 ; ISSN 1664-3224
بيانات النشر: Frontiers Media SA
سنة النشر: 2024
المجموعة: Frontiers (Publisher - via CrossRef)
الوصف: Autoimmune rheumatic diseases (ARDs), such as rheumatoid arthritis, systemic lupus erythematosus, and systemic sclerosis, involve dysregulated immune responses causing chronic inflammation and tissue damage. Despite advancements in clinical management, many patients do not respond to current treatments, which often show limited efficacy due to the persistence of autoreactive B cells. Chimeric antigen receptor (CAR)-T cell therapy, which has shown success in oncology for B cell malignancies, targets specific antigens and involves the adoptive transfer of genetically engineered T cells. CD19 CAR-T cells, in particular, have shown promise in depleting circulating B cells and achieving clinical remission. This review discusses the potential of CD19 CAR-T cells in ARDs, highlighting clinical achievements and addressing key considerations such as optimal target cell populations, CAR construct design, acceptable toxicities, and the potential for lasting immune reset, crucial for the safe and effective adoption of CAR-T cell therapy in autoimmune treatments.
نوع الوثيقة: article in journal/newspaper
اللغة: unknown
DOI: 10.3389/fimmu.2024.1502712
DOI: 10.3389/fimmu.2024.1502712/full
الاتاحة: https://doi.org/10.3389/fimmu.2024.1502712
https://www.frontiersin.org/articles/10.3389/fimmu.2024.1502712/full
Rights: https://creativecommons.org/licenses/by/4.0/
رقم الانضمام: edsbas.5F60BB9D
قاعدة البيانات: BASE
الوصف
DOI:10.3389/fimmu.2024.1502712